Trial Profile
Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Carcinoma; Lung cancer
- Focus Therapeutic Use
- Acronyms Spark-AL003
- 26 Oct 2018 New trial record